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BACKGROUND: Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, 
assessment of response to immunotherapy with the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, could  
result in premature treatment termination. The randomized, open-label, phase 3 CheckMate 141 trial (NCT02105636), which evalu-
ated nivolumab in recurrent/metastatic squamous cell carcinoma of the head and neck after platinum therapy, allowed treatment 
beyond first RECIST-defined progression (TBP) according to protocol-specified criteria. METHODS: In CheckMate 141, patients 
with RECIST-defined progression who had a stable performance status and demonstrated clinical benefit without rapid disease 
progression were permitted to receive TBP with nivolumab at 3 mg/kg every 2 weeks until further progression, which was defined 
as an additional ≥10% increase in tumor volume. This post hoc analysis evaluated outcomes for patients who received TBP with 
nivolumab. RESULTS: Of 240 patients randomized to nivolumab, 146 experienced RECIST-defined progression. Sixty-two of these 
patients received TBP, and 84 discontinued treatment (no TBP). Among the 60 TBP patients evaluable for response, 15 (25%) 
had no change in their tumor burden, and 15 (25%) had reductions in target lesion size; 3 patients (5%) had reductions >30%.  
The median overall survival among TBP patients was 12.7 months (95% confidence interval, 9.7-14.6 months). No new safety signals 
were observed with TBP. Exploratory analyses of immune cell biomarkers suggested a potential relationship with initial and TBP 
responses. CONCLUSIONS: Tumor burden reduction was noted in a proportion of patients who received TBP with nivolumab in 
CheckMate 141. Additional research is warranted to identify factors predictive of a TBP benefit in this population. Cancer 2019;0:1-11. 
© 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access arti-
cle under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 
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INTRODUCTION
Nivolumab demonstrated a significant overall survival (OS) benefit and a favorable safety profile compared with 
 investigator’s choice of therapy in the primary analysis of CheckMate 141 (NCT02105636) in patients with recurrent/ 
metastatic squamous cell carcinoma of the head and neck (SCCHN) who had experienced tumor progression or 
recurrence within 6 months of platinum-based chemotherapy in the adjuvant, primary (ie, with radiation), recurrent, or 
metastatic setting.1 Survival and safety benefits were maintained at the 1- and 2-year follow-up.2,3
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In CheckMate 141, the tumor response was assessed 
with the Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1. The RECIST guidelines, which 
were developed for assessment of chemotherapy-treated 
tumors,4 assume that early tumor growth indicates pro-
gressive disease. With immunotherapy, however, some 
patients exhibit distinct response patterns, including 
apparent increases in tumor size due to immune and 
inflammatory cell infiltration, and/or delayed clinical 
response.5 Therefore, RECIST assessment of a tumor 
response to immunotherapy could result in an incor-
rect diagnosis of disease progression and premature ter-
mination of treatment. In CheckMate 141, treatment 
beyond first RECIST-defined progression (TBP) with 
nivolumab was permitted at the discretion of investiga-
tors, according to protocol-defined criteria, for patients 
who were likely to benefit from continued treatment; 
results from this analysis are reported.
MATERIALS AND METHODS
Patients and Study Design
The full study methodology of the randomized, open-
label, phase 3 CheckMate 141 study has been described 
previously.1 Patients were randomized 2:1 to receive 
intravenous nivolumab at 3 mg/kg every 2 weeks or 
the investigator’s choice, which consisted of intrave-
nous methotrexate (40-60 mg/m2 weekly), docetaxel 
(30-40 mg/m2 weekly), or cetuximab (400 mg/m2 once 
and then 250 mg/m2 weekly). Treatment was continued 
until the occurrence of unacceptable toxicity or disease 
progression except in patients assigned to the nivolumab 
treatment arm who met the protocol-defined criteria for 
TBP. The primary endpoint of the study was OS; pa-
tients were followed up for survival during treatment and 
every 3 months after discontinuation. The objective re-
sponse rate (ORR), defined as the proportion of patients 
with a best overall response of confirmed complete re-
sponse or partial response according to RECIST, version 
1.1, was a secondary endpoint. The tumor response was 
assessed by investigators every 6 weeks beginning week 9. 
The association of immune cell phenotypes with a clinical 
response was assessed as an exploratory endpoint. Safety 
was monitored throughout treatment and for 100 days 
after the administration of the last dose.
CheckMate 141 was approved by institutional review 
boards at all participating sites. Patients provided infor-
med consent before enrollment.
Treatment Beyond First RECIST-Defined 
Progression
Per protocol, TBP was permitted at the discretion of 
 investigators in consultation with the study monitors if a 
patient demonstrated clinical benefit without rapid disease 
progression, tolerated nivolumab, maintained a stable per-
formance status, and provided informed consent. Clinical 
benefit was assessed according to whether the patient was 
clinically deteriorating and unlikely to receive further ben-
efit from continued treatment. TBP was not permitted if 
it would cause a delay in an intervention to prevent serious 
complications from disease progression. Treatment could 
continue until evidence of further progression, which was 
defined as an additional ≥10% increase in the tumor vol-
ume from the time of first progression in all target lesions 
and new measurable lesions.
Patients in the nivolumab arm who received their 
last dose of treatment after RECIST-defined progres-
sion were included in the TBP group; patients whose 
last dose of nivolumab occurred before RECIST-defined 
Figure 1. Patient subgroups for the analysis of treatment beyond first RECIST-defined progression. RECIST indicates Response 
Evaluation Criteria in Solid Tumors.
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progression were included in the no treatment beyond 
first RECIST-defined progression (NTBP) group.
Biomarkers
Blood samples were collected from patients at baseline 
and on day 43 of treatment in Vacutainer CPT cell 
preparation tubes with sodium heparin and were cen-
trifuged according to the manufacturer’s recommended 
procedure to isolate peripheral blood lymphocytes. 
The cells were washed with phosphate-buffered saline 
or Roswell Park Memorial Institute 1640 medium and 
then resuspended in a freezing medium of fetal bovine 
serum plus 10% dimethyl sulfoxide. The cells were 
immediately frozen at –70 °C for up to 72 hours before 
they were moved to long-term storage in liquid nitrogen. 
Frozen peripheral blood lymphocyte (PBL) samples were 
TABLE 1. Characteristics of Patients With RECIST-Defined Progression Treated With Nivolumab
Baseline Characteristics
TBP Patients 
(n = 62)
TBP Patients Who Experienced 
Reductions in Target Lesion  
Size (n = 15)
NTBP Patients 
(n = 84)
Age, median (range), y 59.0 (29-78) 58.0 (29-67) 61.0 (30-83)
Male, No. (%) 52 (84) 14 (93) 71 (85)
Primary site of disease, No. (%)
Oral cavity 26 (42) 3 (20) 33 (39)
Pharynx 28 (45) 9 (60) 36 (43)
Larynx 8 (13) 3 (20) 13 (15)
Othera 0 0 2 (2)
Disease sites (primary and metastatic) per patient, No. (%)b,c 
1 20 (32) 6 (40) 24 (29)
2 27 (44) 5 (33) 26 (31)
3 8 (13) 2 (13) 27 (32)
≥4 7 (11) 2 (13) 7 (8)
ECOG PS, No. (%)
0 21 (34) 3 (20) 17 (20)
1 41 (66) 12 (80) 66 (79)
Not reported 0 0 1 (1)
HPV status, No. (%)d 
Positive 21 (34) 8 (53) 21 (25)
Negative 19 (31) 4 (27) 17 (20)
Unknown/not reported 22 (35) 3 (20) 46 (55)
PD-L1 expression, No. (%)
≥1% 27 (44) 5 (33) 28 (33)
<1% 17 (27) 6 (40) 30 (36)
Not quantifiable at baseline 18 (29) 4 (27) 26 (31)
Lactate dehydrogenase
Median (range), U/L 210.0 (97-1799)e 188.0 (114-919) 252.5 (94-4138)
Normal, No. (%) 47 (77)e 10 (67) 62 (74)
High, No. (%) 14 (23)e 5 (33) 22 (26)
Tobacco use, No. (%)
Current/former 49 (79) 13 (87) 71 (85)
Never 12 (19) 2 (13) 10 (12)
Unknown 1 (2) 0 3 (4)
Characteristics at First RECIST-Defined Progression
TBP Patients  
(n = 62)
NTBP Patients 
(n = 84)
ECOG PS, No. (%)
0 22 (35) 11 (13)
1 40 (65) 32 (38)
2 0 7 (8)
Not reported 0 34 (40)
Type of RECIST progression, No. (%)
Target lesion 38 (61) 47 (56)
New lesion 3 (5) 4 (5)
Both 21 (34) 33 (39)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; NTBP, no treatment beyond first RECIST-defined progression; 
PD-L1, programmed death ligand 1; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; TBP, treatment beyond first RECIST-
defined progression.
aOther includes patients with a tumor in more than 1 of the 3 categories (ie, larynx, oral cavity, and pharynx).
bPatients could have had lesions at more than 1 site.
cBoth target and nontarget lesions are included.
dThe HPV status was assessed with p16 immunohistochemical testing and was required only for patients with oropharyngeal cancer.
eData were available for 61 patients; percentages were calculated with 61 as the denominator.
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shipped to the analyzing laboratory in liquid nitrogen 
vapor shippers.
At the laboratory, vials were thawed in a water 
bath at 37°C for 1 minute; then, the sample from each 
vial was transferred into a 15-mL conical tube con-
taining warm Roswell Park Memorial Institute 1640 
medium, washed twice by sequential centrifugation, 
resuspended in 5 mL of phosphate-buffered saline and 
stained with viability dye Zombie Aqua (BioLegend, 
San Diego, California) according to the manufacturer’s 
protocol, and then stained for multicolor flow cytom-
etry. Samples were stained for CD8+ T cells with the 
following mouse anti-human monoclonal antibodies: 
TCRα/β AF700, CD8 APC-Cy7, CCR7-BV650, and 
CD45RA-BV711. Samples were stained for regulatory 
T cells with the following mouse anti-human antibod-
ies: CD4-AF700, CD25-BV650, CD127-BV785, and 
FOXP3-PerCPCy5.5. All antibodies were purchased 
from BD Bioscience (San Jose, California). Mouse anti- 
human PD-1-APC (clone MIH4; eBioscience), cyto-
toxic T lymphocyte antigen 4 (CTLA-4)–PECy5 (clone 
BNI3; BD Bioscience), and T cell immunoglobulin and 
mucin-domain containing-3 (TIM-3)–APCCy7 or PE 
(clone F38-2E2; BioLegend) were also added to CD8+ 
T cell and regulatory T cell panels with staining per-
formed according to manufacturer protocols. Cells from 
each sample were analyzed with the BD Fortessa flow 
cytometer (BD Bioscience, San Diego, California) and 
FlowJo v10 software (FlowJo, Ashland, Oregon).
Differences in biomarker profiles between TBP 
patients who had a reduction in target lesions after 
postprogression nivolumab treatment (TBP respond-
ers) and TBP patients who had no change or an incre-
ase in target lesions after postprogression treatment 
(TBP nonresponders) were assessed for association 
with response to therapy. To serve as control, bio-
marker assessments were also performed for patients 
with a RECIST-defined best response of complete 
or partial response who had not progressed as of the 
data cutoff (RECIST responders) and for patients with 
RECIST-defined progressive disease as of the data cut-
off (RECIST nonresponders). In addition, immune 
cell phenotype expression was assessed for similarities 
 between RECIST and TBP responders.
Statistical Analysis
Only patients from the nivolumab arm were included in 
the TBP analysis of clinical outcomes. OS was estimated 
with the Kaplan-Meier methodology6; 2-sided 95% con-
fidence intervals (CIs) for median OS were computed 
with a generalization of the Brookmeyer and Crowley 
method.7 Two-sided 95% CIs for ORRs were computed 
with the Clopper and Pearson method.8 A 2-way anal-
ysis of variance with Šidák’s multiple comparisons test 
correction was used to descriptively analyze the PBL 
biomarker data.9,10 The database lock for efficacy and 
safety was September 2016, which represented a mini-
mum  follow-up of 11.8 months. The database lock for 
biomarkers was August 2017.
The Bristol-Myers Squibb policy on data sharing 
can be found at https ://www.bms.com/resea rchers-and-
partn ers/indep endent-resea rch/data-shari ng-reque st-
proce ss.html.
RESULTS
Patients
Of 240 patients randomized to nivolumab, 146 (61%) 
experienced RECIST-defined progression (Fig. 1). Sixty-
two of these patients (42%) met the criteria for TBP and 
continued to receive nivolumab treatment; 84 (58%) dis-
continued treatment (NTBP). Among the remaining 94 of 
240 patients (39%), 4 did not receive nivolumab, 11 were 
continuing treatment as of the data cutoff, and the rest 
discontinued treatment primarily because of either a lack 
of confirmation of disease progression or adverse events.
Patient characteristics at baseline and at RECIST-
defined progression are summarized in Table 1. Overall, 
the baseline characteristics were similar between patients 
in the 2 groups, although a larger percentage of TBP 
patients had a baseline Eastern Cooperative Oncology 
Group performance status of 0. The most common 
TABLE 2. Efficacy in the TBP and NTBP Patient 
Groups Before First RECIST-Defined Progression
TBP Group 
(n = 62)
NTBP Group 
(n = 84)
Best overall response, No. (%)
Partial response 10 (16) 5 (6)
Stable disease 20 (32) 17 (20)
Progressive disease 32 (52) 62 (74)
Objective response rate, No. (%) 10 (16) 5 (6)
95% CI 8-28 2-13
Maximum reduction in target  
lesion, median (range), %a
7 (−86 to 129) 23 (−85 to 162)
Time to response,  
median (range), mob 
2.1 (1.8-4.8) 2.0 (1.8-5.1)
Duration of response,  
median (range), mob 
6.4 (2.8-9.7) 5.5 (4.0-6.9)
Abbreviations: CI, confidence interval; NTBP, no treatment beyond first 
RECIST-defined progression; RECIST, Response Evaluation Criteria in 
Solid Tumors; TBP, treatment beyond first RECIST-defined progression.
aEvaluated for 60 patients in the TBP group and 79 patients in the NTBP 
group.
bFor responders (10 in the TBP group and 5 in the NTBP group).
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sites of metastases at baseline were similar between the 
TBP group (lung, 53%; lymph nodes, 48%) and the 
NTBP group (lung, 52%; lymph nodes, 54%). In both 
groups, RECIST-defined progression in the majority of 
 patients was due to an increase in the size of target lesions 
either with (TBP, 34%; NTBP, 39%) or without the 
development of new lesions (TBP, 61%; NTBP, 56%; 
Table 1).
Efficacy
The ORR before RECIST-defined progression was 
higher in the TBP group (16%) than the NTBP group 
(6%; Table 2). Of the 62 patients who underwent 
TBP with nivolumab, 60 were evaluable for response; 
15 (25%) had no change in their tumor burden, and 
15 (25%) had reductions in the target lesion size. Three 
patients (5%) had a reduction >30% (Fig. 2). For 9 
of the 15 patients with reductions in the target lesion 
size (60%), the pharynx was the primary site of disease 
(Table 1). Five of the 15 patients with tumor reductions 
after TBP had previously experienced a >20% increase 
in the target lesion size at RECIST-defined progression, 
and only 1 had a preprogression best overall response 
of partial response. The median time to tumor burden 
reduction among the 15 patients with reductions after 
RECIST-defined progression was 3.9 months (range, 
3.1-15.8), and the median duration of tumor reduc-
tion was 3.0 months (range, <0.1-15.4+). Reductions 
were observed in patients with human papillomavirus 
(HPV)-positive and HPV-negative tumors as well as 
those with tumor programmed death ligand 1 (PD-L1) 
expression ≥1% or <1%.
Among patients receiving TBP with nivolumab, the 
median OS was 12.7 months (95% CI, 9.7-14.6 months; 
Fig. 3A); the estimated OS rates for these patients at 
12 and 18 months were 52% and 30%, respectively. In 
the overall intent-to-treat population (including patients 
in the TBP and NTBP groups as well as those who did 
not experience RECIST-defined progression), the me-
dian OS for nivolumab-treated patients was 7.7 months 
(95% CI, 5.7-8.8 months; Fig. 3B).2 In a landmark 
analysis, the median OS starting week 6 after RECIST-
defined progression was 8.4 months (95% CI, 6.6-10.8 
months) in the TBP group and 3.8 months (95% CI, 2.1-
5.3 months) in the NTBP group (Fig. 4).
Biomarkers
Peripheral blood lymphocyte samples from baseline and 
day 43 of treatment were available for 14 TBP patients; 
3 of these patients were TBP responders, and 11 were 
TBP nonresponders. In addition, samples were available 
for 26 patients assessed with RECIST (16 responders and 
10 nonresponders). Across all immune cell phenotypes, 
there were no significant differences in baseline biomarker 
levels between RECIST and TBP responders. Differences 
in the levels of total CD8+ T cells, PD-1+ CD8+ effec-
tor T cells, and exhausted PD-1+ TIM-3+ CD8+ effector 
T cells as well as PD-1+ regulatory T cells and CTLA-4+ 
Figure 2. Tumor reduction in patients treated beyond first RECIST-defined progression with nivolumab. HPV indicates human 
papillomavirus; PD-L1, programmed death ligand 1; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.
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regulatory T cells were noted between responders and 
nonresponders (RECIST and/or TBP) at baseline and/or 
day 43, although not all differences were significant 
(Fig. 5A,B). There was a wide variation in the levels of 
CTLA-4+ CD8+ effector T cells. Among TBP responders 
(n = 3), there was a significant reduction in PD-1+ regu-
latory T cell levels on day 43 in comparison with baseline; 
this difference was not noted in nonresponders (n = 11). 
In contrast, the CD8+ T cell compartment did not show 
any significant differences between TBP  responders and 
nonresponders after nivolumab treatment.
Safety
Treatment-related adverse events (TRAEs) and select 
TRAEs are summarized in Table 3. When adjusted for du-
ration of therapy exposure, the incidence of TRAEs, with 
the exception of skin and subcutaneous tissue disorders, was 
lower in the TBP group than the NTBP group (Table 4).
Figure 3. (A) OS in patients treated beyond first RECIST-defined progression with nivolumab. (B) OS in the overall intent-to-
treat population of patients (nivolumab arm). CI indicates confidence interval; OS, overall survival; RECIST, Response Evaluation 
Criteria in Solid Tumors. Reprinted with permission from AlphaMed Press from CheckMate 141: 1-Year Update and Subgroup 
Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer, Gillison, Oncologist 
23(9), 2018, permission conveyed through Copyright Clearance Center, Inc.2
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DISCUSSION
In this post hoc analysis of CheckMate 141, tumor bur-
den reduction was noted in 15 of 60 patients (25%) who 
underwent TBP with nivolumab; 3 patients (5%) expe-
rienced a reduction >30%. In the context of all  patients 
randomized to receive nivolumab in the trial, this trans-
lates to an efficacy benefit of treatment beyond progression 
in 1.3% (3 of 240). The median OS was 12.7 months for 
patients receiving TBP with nivolumab and 7.7 months 
in the overall intent-to-treat population.2 In a landmark 
analysis, the median OS starting week 6 after RECIST-
defined progression was 8.4 months for the TBP group 
and 3.8 months for the NTBP group. No new safety sig-
nals were noted with TBP. Efficacy benefits after TBP with 
nivolumab have also been reported for melanoma,11,12 
non–small cell lung cancer,13 and renal cell carcinoma.14,15
In CheckMate 141, the ORR before RECIST-
defined progression was higher in the TBP group than 
Figure 4. Landmark analysis of OS starting from week 6 after first RECIST-defined progression in (A) the TBP group and (B) the 
NTBP group. CI indicates confidence interval; NTBP, no treatment beyond first RECIST-defined progression; OS, overall survival; 
RECIST, Response Evaluation Criteria in Solid Tumors; TBP, treatment beyond first RECIST-defined progression.
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the NTBP group; this was expected on the basis of the 
protocol-defined requirement that patients demonstrate 
an investigator-assessed clinical benefit to be eligible 
for TBP. The characteristics of the TBP and NTBP pa-
tients were similar at baseline except for a better Eastern 
Cooperative Oncology Group performance status in the 
TBP group. These findings are similar to those reported in 
a recent pooled TBP analysis conducted by the US Food 
and Drug Administration in patients with melanoma.12 
Among the 15 TBP patients in this analysis who achieved 
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any reduction in the target lesion size after progression, 
8 (53%) had HPV-positive cancers.
It is important to note that although interest-
ing, the small patient numbers in our study preclude 
us from drawing definitive conclusions about patient 
characteristics predictive of clinical benefit from treat-
ment with nivolumab beyond RECIST-defined progres-
sion. The criteria for TBP used in this analysis are similar 
to those used for TBP with nivolumab in reports for other 
tumors. Nonetheless, a key limitation of the analysis is 
Figure 5. (A) Levels of CD8+ effector T cells among RECIST-defined responders, RECIST-defined nonresponders, responders to 
treatment beyond first RECIST-defined progression, and nonresponders to treatment beyond first RECIST-defined progression. 
(B) Levels of regulatory T cells among the RECIST-defined responders, RECIST-defined nonresponders, responders to treatment 
beyond first RECIST-defined progression, and nonresponders to treatment beyond first RECIST-defined progression. Dark 
blue bars represent baseline values; light blue bars represent day 43 values. Horizontal lines indicate medians, boxes indicate 
interquartile ranges, and whiskers indicate minimum and maximum values. CD8+ effector T cells were defined as TCRα/
β+CD8+CCR7–CD45RA+. PD-1+ TIM-3+ CD8+ cells were considered to be exhausted CD8+ effector T cells. Regulatory T cells 
were defined as CD4+CD25hiCD127loFoxP3+. *P < .05; **P < .01; ***P < .001. CR indicates complete response; CTLA-4, cytotoxic 
T lymphocyte antigen 4; PD, progressive disease; PD-1, programmed cell death 1; PR, partial response; RECIST, Response 
Evaluation Criteria in Solid Tumors; TBPNR, treatment beyond first RECIST-defined progression with stable or increased 
tumor lesion after progression; TBPR, treatment beyond first RECIST-defined progression with reduction in tumor lesion after 
progression; TIM-3, T cell immunoglobulin and mucin-domain containing-3.
TABLE 3. TRAEs Reported in ≥10% of Patients and Select TRAEs
TBP Patients (n = 62) NTBP Patients (n = 84)
Any Grade Grade 3-4 Any Grade Grade 3-4
Any TRAE, No. (%) 48 (77) 9 (15) 51 (61) 12 (14)
Fatigue 10 (16) 1 (2) 17 (20) 2 (2)
Rash 10 (16) 0 6 (7) 0
Pruritus 9 (15) 0 3 (4) 0
Anemia 3 (5) 1 (2) 9 (11) 2 (2)
Decreased appetite 3 (5) 0 10 (12) 0
Select TRAEs, No. (%)
Skin 19 (31) 0 10 (12) 0
Endocrine 8 (13) 0 8 (10) 0
Gastrointestinal 6 (10) 0 8 (10) 1 (1)
Hepatic 3 (5) 0 2 (2) 1 (1)
Pulmonary 2 (3) 0 3 (4) 1 (1)
Hypersensitivity/infusion reactions 1 (2) 0 1 (1) 0
Renal 1 (2) 0 0 0
Abbreviations: NTBP, no treatment beyond first RECIST-defined progression; RECIST, Response Evaluation Criteria in Solid Tumors; TBP, treatment beyond 
first RECIST-defined progression; TRAE, treatment-related adverse event.
TABLE 4. Exposure-Adjusted Incidence of Treatment-Related Adverse Events in ≥10% of Patients
TBP Patients (n = 62)a NTBP Patients (n = 84)b 
Events, No. Rate per 100 P-Yc Events, No. Rate per 100 P-Yc 
Total events 184 489 150 618
Skin and subcutaneous tissue disorders 43 114 13 54
Rash 14 37 6 25
Pruritus 9 24 4 16
General disorders and administration site 
conditions
26 69 29 119
Fatigue 10 27 18 74
Metabolism and nutrition disorders 17 45 19 78
Decreased appetite 5 13 11 45
Blood and lymphatic system disorders 5 13 12 49
Anemia 3 8 9 37
Abbreviations: NTBP, no treatment beyond first RECIST-defined progression; P-Y, person-years of exposure; RECIST, Response Evaluation Criteria in Solid 
Tumors; TBP, treatment beyond first RECIST-defined progression.
a37.6 P-Y.
b24.3 P-Y.
cIncidence rate per 100 P-Y = number of events × 100/P-Y.
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that the selection of patients for TBP with nivolumab was 
based on an assessment of clinical benefit by investigators 
and not on clearly defined, validated factors. Therefore, it 
is possible that the results of this analysis are confounded 
by selection bias because patients with more favorable 
disease characteristics and better prognosis were probably 
selected for inclusion in the TBP group. Despite the lim-
itations, our analysis underscores the potential benefits of 
TBP with nivolumab and the need for identifying factors 
predictive of TBP benefit in this patient population.
Exploratory analyses of cellular immune biomarkers 
suggested a potential relationship with initial and TBP 
responses. TBP with nivolumab appeared to dimin-
ish immunosuppressive signals from PD-1+ regulatory 
T cells. It should be noted, however, that the sample sizes 
were small, and this research should be considered hy-
pothesis-generating. Comprehensive analyses involving 
larger patient populations in prospective clinical trials 
are warranted to fully understand these effects. In this 
study, on-treatment PBL samples were collected on day 
43 of treatment, a prespecified time point for the collec-
tion of on-treatment PBL samples. The timing was based 
on the assumption that 6 weeks was adequate to evalu-
ate changes in frequencies in the adaptive immune cell 
compartment in comparison with baseline values and to 
assess the expression of markers of activation or exhaus-
tion. However, the timing of the PBL sample collection 
was independent of the timing of the tumor response; this 
could have resulted in a large variability in on-treatment 
biomarker levels.
Because of the limitations of RECIST in accu-
rately characterizing tumor responses to immunother-
apy, guidelines such as immune-related response criteria 
(irRC),5 immune-related RECIST (irRECIST) and 
 immune-modified RECIST (imRECIST),16-19 and mod-
ified RECIST, version 1.1, for immune-based therapeu-
tics (iRECIST)20 have been developed. The goal of these 
guidelines is 2-fold: to ensure that treatment is not pre-
maturely terminated for patients with tumor responses to 
immunotherapy that are different from responses typical 
of cytotoxic chemotherapy and to ensure that treatment 
is discontinued in a timely manner in patients with true 
disease progression because this can affect potential ben-
efits from subsequent lines of treatment.20
In summary, patients with RECIST-defined 
progression who do not experience rapid disease pro-
gression, have a stable performance status, and are 
able to tolerate treatment may derive a clinical bene-
fit from TBP with nivolumab for recurrent/metastatic 
SCCHN. Our results underscore the importance of 
conducting prospective trials aimed at evaluating the 
eligibility and appropriate selection of patients who 
may derive a benefit from TBP. Additional research is 
also needed to determine whether a response to TBP 
can be predicted on the basis of immunologic factors 
or patient clinical characteristics. Our results indicate 
that continued TBP with nivolumab is not associated 
with new safety concerns.
FUNDING SUPPORT
This study was funded by Bristol-Myers Squibb.
CONFLICT OF INTEREST DISCLOSURES
Robert Haddad has received grants from Bristol-Myers Squibb, Merck, 
Celgene, Kura, Pfizer, and AstraZeneca and has received personal fees 
from Bristol-Myers Squibb, Merck, Celgene, Pfizer, AstraZeneca, 
GlaxoSmithKline, Nanobiotix, and Eisai. George Blumenschein, Jr, 
has received grants from Adaptimmune, AstraZeneca, Bristol-Myers 
Squibb, Celgene, Exelixis, Genentech, GlaxoSmithKline, Immatics, 
Immunocore, Incyte, Kite Pharma, Macrogenics, Medimmune, Merck, 
Novartis, Roche, Torque, and Xcovery and has received personal fees 
from AbbVie, Adicet, Amgen, Ariad, AstraZeneca, Bayer, Bristol-Myers 
Squibb, Celgene, Clovis, Genentech, Johnson & Johnson, Maverick 
Therapeutics, MedImmune, Merck, Novartis, Roche, Virogin Biotech, 
and Xcovery. Jerome Fayette has received grants from AstraZeneca, 
Bristol-Myers Squibb and has received other support from AstraZeneca, 
Bristol-Myers Squibb, Merck Sharp & Dohme, Merck Serono, Innate 
Pharma, Biogen. Joel Guigay has received grants from GlaxoSmithKline, 
Bristol-Myers Squibb, and Merck KGaA and has received other support 
from AstraZeneca, Bristol-Myers Squibb, Innate Pharma, Nanobiotix, 
and Merck KGaA. A. Dimitrios Colevas reports personal fees from Aduro 
Biotech, Inc., ATARA Biotherapeutics, Cue Biopharma, Inc., COTA, 
Inc, KeyQuest Health, LOXO Oncology, Pfizer DSMB, and has received 
research/grant support from Abbvie, Atara, AstraZeneca, Bristol-Myers 
Squibb, Cullinan, CellSight Technologies, Inc.,  Exelixis, Innate Pharma, 
Tessa Therapeutics, and Threshhold Pharmaceuticals. Lisa Licitra has re-
ceived grants/research support from AstraZeneca, Boehringer Ingelheim, 
Bristol-Myers Squibb, Celgene International, Eisai, Exelixis, Hoffmann–
La Roche, IRX Therapeutics, Medpace, Merck Serono, Merck Sharp & 
Dohme, Novartis, Pfizer, and Roche; has received honoraria/consultation 
fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-
Myers Squibb, Debiopharm, Doxa Pharma SRL, Eisai, Health & Life 
SRL, Immuno-Oncology Hub, Incyte Biosciences Italy SRL, Ipsen 
Innovation, Kura Oncology, Merck Serono, Merck Sharp & Dohme, 
Nanobiotics SA, Novartis, Roche, and SOBI; and has received other 
support from Bayer, Bristol-Myers Squibb, Debiopharm, Merck Serono, 
Merck Sharp & Dohme, and SOBI. Stefan Kasper has received per-
sonal fees and other support from Amgen, AstraZeneca, Bristol-Myers 
Squibb, Celgene, Eli Lilly, Merck Serono, Merck Sharp & Dohme, and 
Roche. Everett E. Vokes has received personal fees from AbbVie, Amgen, 
AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Merck, and 
Regeneron. Francis Worden has received personal fees from Merck and 
other support from Bristol-Myers Squibb. Nabil F. Saba has received other 
support from Merck, Bristol-Myers Squibb, and Lilly. Dr. Saba has re-
ceived other support from Bristol-Myers Squibb, Lilly, Merck, and Pfizer. 
Makoto Tahara has received grants from Ono Pharmaceutical, Bristol-
Myers Squibb, Eisai, Otsuka, Boehringer Ingelheim, AstraZeneca, Pfizer, 
Novartis, and NanoCarrier and has received personal fees from Ono 
Pharmaceutical, Bristol-Myers Squibb, Merck Sharp & Dohme, Bayer, 
Eisai, Otsuka, AstraZeneca, and Pfizer. Vijayvel Jayaprakash is an em-
ployee of Bristol-Myers Squibb and a former employee of AstraZeneca. 
Mark Lynch is a former employee of Bristol-Myers Squibb. Li Li is an 
employee of Bristol-Myers Squibb. Maura L. Gillison has received other 
support from Merck, Bristol-Myers Squibb, Amgen, AstraZeneca, 
Celgene, and Aspyrian. Kevin J. Harrington has received grants from 
AstraZeneca and Merck Sharp & Dohme and has received other support 
TBP with nivo in SCCHN in CheckMate 141/Haddad et al
11Cancer  Month 0, 2019
from AstraZeneca, Bristol-Myers Squibb, Merck Serono, Merck Sharp 
& Dohme, and Pfizer. Robert L. Ferris has received grants/research 
and clinical trial support from AstraZeneca/MedImmune, Bristol-
Myers Squibb, Merck, Tesaro, and VentiRx Pharmaceuticals and has 
received advisory board/consultation fees from Amgen, AstraZeneca/
MedImmune, Bain Capital Life Sciences, Bristol-Myers Squibb, EMD 
Serono, GlaxoSmithKline, Iovance Biotherapeutics, Lilly, Merck, Numab 
Therapeutics, Oncorus, Ono Pharmaceuticals, Pfizer, PPD, Regeneron 
Pharmaceuticals, Tesaro, Torque Therapeutics, and TTMS; he is also 
supported by the P50 CA097190-14, P30 CA047904-28, and R01 
CA206517 grants. The other authors made no disclosures.
AUTHOR CONTRIBUTIONS
Robert Haddad: Acquisition of data; analysis and interpretation; and 
writing, review, and/or revision of the manuscript. Fernando Concha-
Benavente: Acquisition of data; analysis and interpretation; and writing, 
review, and/or revision of the manuscript. George Blumenschein, Jr: 
Acquisition of data; analysis and interpretation; and writing, review, and/or 
revision of the manuscript. Jerome Fayette: Acquisition of data; analy-
sis and interpretation; and writing, review, and/or revision of the manu-
script. Joel Guigay: Acquisition of data; analysis and interpretation; 
and writing,  review, and/or revision of the manuscript. A. Dimitrios 
Colevas: Acquisition of data; analysis and interpretation; and writing, 
review, and/or revision of the manuscript. Lisa Licitra: Acquisition of 
data; analysis and interpretation; and writing, review, and/or revision 
of the manuscript. Stefan Kasper: Acquisition of data; analysis and in-
terpretation; and writing, review, and/or revision of the manuscript. 
Everett E. Vokes: Acquisition of data; analysis and interpretation; and 
writing, review, and/or revision of the manuscript. Francis Worden: 
Acquisition of data; analysis and interpretation; and writing, review, 
and/or revision of the manuscript. Nabil F. Saba: Acquisition of data; 
analysis and interpretation; and writing, review, and/or revision of the 
manuscript. Makoto Tahara: Acquisition of data; analysis and interpre-
tation; and writing, review, and/or revision of the manuscript. Vijayvel 
Jayaprakash: Analysis and interpretation and writing, review, and/or 
revision of the manuscript. Mark Lynch: Conception and design; develop-
ment of methodology; analysis and interpretation; and writing, review, and/or 
revision of the manuscript. Li Li: Conception and design; development 
of methodology; analysis and interpretation; and writing, review, and/or 
revision of the manuscript. Maura L. Gillison: Conception and design; 
development of methodology; acquisition of data; analysis and interpre-
tation; and writing, review, and/or revision of the manuscript. Kevin J. 
Harrington: Acquisition of data; analysis and interpretation; and writing, 
review, and/or revision of the manuscript. Robert L. Ferris: Conception 
and design; development of methodology; acquisition of data; analysis 
and interpretation; and writing, review, and/or revision of the manuscript.
REFERENCES
 1. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recur-
rent squamous-cell carcinoma of the head and neck. N Engl J Med. 
2016;375:1856-1867.
 2. Gillison ML, Blumenschein G Jr, Fayette J, et al. CheckMate 141: 
1-year update and subgroup analysis of nivolumab as first-line ther-
apy in patients with recurrent/metastatic head and neck cancer. 
Oncologist. 2018;23:1079-1082.
 3. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investiga-
tor’s choice in recurrent or metastatic squamous cell carcinoma of the 
head and neck: 2-year long-term survival update of CheckMate 141 
with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51.
 4. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response 
Evaluation Criteria in Solid Tumours: revised RECIST guideline 
(version 1.1). Eur J Cancer. 2009;45:228-247.
 5. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation 
of immune therapy activity in solid tumors: immune-related response 
criteria. Clin Cancer Res. 2009;15:7412-7420.
 6. Kaplan EL, Meier P. Nonparametric estimation from incomplete 
 observations. J Am Stat Assoc. 1958;53:457-481.
 7. Brookmeyer R, Crowley J. A confidence interval for the median sur-
vival time. Biometrics. 1982;38:29-41.
 8. Clopper C, Pearson ES. The use of confidence or fiducial limits illus-
trated in the case of the binomial. Biometrika. 1934;26:404-413.
 9. Abdi H. The Bonferroni and Šidák corrections for multiple com-
parisons. In: Salkind NJ, ed. Encyclopedia of Measurement and 
Statistics. Thousand Oaks, CA: Sage; 2007:103-107.
 10. Sheskin DJ. Handbook of Parametric and Nonparametric Statistical 
Procedures. 5th ed. Boca Raton, FL: Chapman & Hall/CRC; 2011.
 11. Long GV, Weber JS, Larkin J, et al. Nivolumab for patients with 
advanced melanoma treated beyond progression: analysis of 2 phase 3 
clinical trials. JAMA Oncol. 2017;3:1511-1519.
 12. Beaver JA, Hazarika M, Mulkey F, et al. Patients with melanoma 
treated with an anti–PD-1 antibody beyond RECIST progression: 
a US Food and Drug Administration pooled analysis. Lancet Oncol. 
2018;19:229-239.
 13. Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. 
Characterization of outcomes in patients with metastatic non–small 
cell lung cancer treated with programmed cell death protein 1 inhib-
itors past RECIST version 1.1–defined disease progression in clinical 
trials. Semin Oncol. 2017;44:3-7.
 14. Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progres-
sion in patients with advanced renal cell carcinoma treated with 
nivolumab in CheckMate 025. Eur Urol. 2017;72:368-376.
 15. George S, Motzer RJ, Hammers HJ, et al. Safety and efficacy of 
nivolumab in patients with metastatic renal cell carcinoma treated 
beyond progression: a subgroup analysis of a randomized clinical 
trial. JAMA Oncol. 2016;2:1179-1186.
 16. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, 
Hodi FS. Developing a common language for tumor response to 
immunotherapy: immune-related response criteria using unidimen-
sional measurements. Clin Cancer Res. 2013;19:3936-3943.
 17. Bohnsack O, Ludajic K, Hoos A. Adaptation of the immune- 
related response criteria: irRECIST [abstract 1070P]. Ann Oncol. 
2014;25(suppl 4):iv361-iv372.
 18. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune- 
related response criteria and RECIST v1.1 in patients with advanced 
melanoma treated with pembrolizumab. J Clin Oncol. 2016;34: 
1510-1517.
 19. Hodi FS, Ballinger M, Lyons B, et al. Immune-modified response 
evaluation criteria in solid tumors (imRECIST): refining guidelines 
to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 
2018;36:850-858.
 20. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for 
 response criteria for use in trials testing immunotherapeutics. Lancet 
Oncol. 2017;18:e143-e152.
